Source:http://linkedlifedata.com/resource/pubmed/id/20570288
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
2010-7-8
|
pubmed:abstractText |
Point mutations in the mitochondrial genome are associated with a variety of metabolic disorders. The myopathy, encephalopathy, lactic acidosis, stroke-like episodes syndrome (MELAS), is most frequently associated with an A to G transition at position 3243 of the mitochondrial tRNA(Leu(UUR)) gene, and is characterized by biochemical and structural alterations of mitochondria. In the present study, we analyzed proteomic changes in an immortalized B-cell line harbouring the MELAS A3243G mutation by two-dimensional difference gel electrophoresis and immunoblot analysis. Although the cell line contained only 10% mutated mitochondrial genomes, we detected significant alterations in numerous proteins associated with the actin cytoskeleton and in nuclear-encoded subunits of mitochondrial respiratory chain complexes. Notably, mitochondrial Lon protease and Hsp60 were deregulated in MELAS cells, indicating an effect on the mitochondrial protein quality control system. By immunofluorescence microscopy, we detected mitochondrial Lon protease accumulation and changes in actin-binding proteins preferentially in MELAS cells containing numerous mitochondria with mutated genomes. Enzymatic assays revealed that Lon protease activity is increased in MELAS cell lysates. Although Lon protease has been shown to degrade misfolded proteins and to stabilize respiratory chain complexes within mitochondria, our MELAS cell line exhibited a higher sensitivity to mitochondrial stress. These findings provide novel insights into the cellular response to dysfunctional mitochondria containing mutated genomes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1878-5883
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright (c) 2010 Elsevier B.V. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
295
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
46-52
|
pubmed:meshHeading |
pubmed-meshheading:20570288-Actins,
pubmed-meshheading:20570288-Cytoskeleton,
pubmed-meshheading:20570288-DNA, Mitochondrial,
pubmed-meshheading:20570288-Electrophoresis, Gel, Two-Dimensional,
pubmed-meshheading:20570288-Humans,
pubmed-meshheading:20570288-Lymphocytes,
pubmed-meshheading:20570288-MELAS Syndrome,
pubmed-meshheading:20570288-Mass Spectrometry,
pubmed-meshheading:20570288-Membrane Potential, Mitochondrial,
pubmed-meshheading:20570288-Mitochondrial Proteins,
pubmed-meshheading:20570288-Mutation,
pubmed-meshheading:20570288-Proteome
|
pubmed:year |
2010
|
pubmed:articleTitle |
Activation of the mitochondrial protein quality control system and actin cytoskeletal alterations in cells harbouring the MELAS mitochondrial DNA mutation.
|
pubmed:affiliation |
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|